Probiotic supplementation in patients with chronic liver disease, resulting from the hepatitis C virus

Probiotic supplementation in patients with chronic liver disease, resulting from the hepatitis C virus - ProbioC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00007817

Enrollment

Registered

2015-02-16

Start date

2013-07-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 B18.2

Interventions

Group 1: The intervention group receives the probiotic strains (lactobacillus helveticus and Bifidobacterium Longum) p.o. once a day for 60 days. At 30 and 60 days, patients will be assessed for sever

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with the chronic hepatitis C virus infection and depression

Exclusion criteria

Exclusion criteria: - Severe hepatic encephalopathy (i.e. CCF score 16) -Intake of pre or probiotic products within previous four weeks -Participation in a clinical trial with investigational drug/device during past month before enrolment

Design outcomes

Primary

Measure	Time frame
change in depression score using BDI-II from baseline to 30 and 60 days (after probiotic I placebo supplementation).	—

Secondary

Measure	Time frame
- changes in intestinal flora after 30 and 60 days of probiotic/placebo supplementation - changes in serum LFTS (ALT, AST, AP, GGT, Bilirubin, Albumin) after 30 and 60 days of a probiotic/placebo supplementation	—

Countries

Germany

Contacts

Public ContactCaroline Stokes

Saarland University Medical Center, Department of Internal Medicine II

caroline.stokes@uks.eu+4968411623222

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026